Chronic Lymphoid Leukemia (CLL)
DCDS4501A for Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia (FH 2501)
An Open-Label, Multicenter, Phase I Trial of the Safety and Pharmacokinetics of Escalating Doses of DCDS4501A in Patients With Relapsed or Refractory B-Cell Non Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia
Investigator: Oliver Press, M.D.; Conditions: Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia; Status: Closed; Study ID: NCT01290549
A Phase II Study of Fludarabine (F), Rituximab (R) and Avastin (A) Followed by RA Maintenance Therapy in Patients with Relapsed/Refractory B-cell Chronic Lymphocytic Leukemia (CLL)
Investigator: John Pagel, MD, PhD; Conditions: Chronic Lymphoid Leukemia (CLL); Status: Closed; Study ID: NCT00845104
A Study of 131-Tositumomab (Bexxar) Consolidation In Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma In First Remission
Investigator: John M. Pagel, MD, PhD; Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma; Status: Recruiting; Study ID: NCT00476047
A Phase I/II Study of Fludarabine (F), Cyclophosphamide ©), Rituximab ®), and Vorinostat (V) Followed by RV Maintenance Therapy in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia or Small LymphoCtic Lymphoma (SLL)
Investigator: John Pagel, MD, PhD; Conditions: Leukemia, Lymphoma; Status: Recruiting; Study ID: NCT00918723
A Phase 1b/2 Open Label Study to Evaluate the Safety and Efficacy of TRU-016 in Combination with Bendamustine vs. Bendamustine Alone in Patients with Relapsed Chronic Lymphocytic Leukemia
Investigator: John Pagel, MD, PhD; Conditions: Chronic Lymphocytic Leukemia (CLL); Status: Recruiting; Study ID: NCT01188681
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma
Investigator: John M. Pagel, MD, PhD; Conditions: Chronic Lymphocytic Leukemia, Non-Hodgkin's Lymphoma; Status: Closed; Study ID: NCT01328626
A Phase 3, Double-Blind Extension Study Evaluating the Efficacy and Safety of Two Different Dose Levels of Single-Agent GS 1101 (CAL 101) as Therapy for Patients With Previously Treated Chronic Lymphocytic Leukemia
Investigator: John M. Pagel, MD; Conditions: Chronic Lymphocytic Leukemia; Status: Recruiting; Study ID: NCT01539291
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS 1101 (CAL-101) in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia
Investigator: John M. Pagel, MD; Conditions: Chronic Lymphocytic Leukemia; Status: Pending; Study ID: NCT01539512
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-1101 (CAL-101) in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia
Investigator: John M. Pagel, MD; Conditions: Chronic Lymphocytic Leukemia; Status: Recruiting; Study ID: NCT01569295
Join Us On